On the public citation graph
Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea
0 signed · 74 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jamaoncol.2019.2792openalex-snapshot
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma
inferredcites →https://doi.org/10.1002/cam4.2241openalex-snapshot
Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis
inferredcites →https://doi.org/10.1002/hep.20486openalex-snapshot
Validation of A New Prognostic Staging System for Hepatocellular Carcinoma: the Jis Score Compared With the Clip Score
inferredcites →https://doi.org/10.1002/hep.24199openalex-snapshot
Management of Hepatocellular Carcinoma: An Update Δσ
inferredcites →https://doi.org/10.1002/hep.510280322openalex-snapshot
A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients
inferredcites →https://doi.org/10.1002/jgh3.12209openalex-snapshot
Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real‐world setting
inferredcites →https://doi.org/10.1007/s00535-016-1263-4openalex-snapshot
Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
inferredcites →https://doi.org/10.1016/s0140-6736(18)30207-1openalex-snapshot
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
inferredcites →https://doi.org/10.1055/s-0030-1247132openalex-snapshot
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
inferredcites →https://doi.org/10.1056/nejmoa0708857openalex-snapshot
Sorafenib in Advanced Hepatocellular Carcinoma
inferredcites →https://doi.org/10.1080/17474124.2017.1373018openalex-snapshot
Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis
inferredcites →https://doi.org/10.1155/2000/617428openalex-snapshot
Thrombocytopenia in Liver Disease
inferredcites →https://doi.org/10.1159/000462153openalex-snapshot
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib.
inferredcites →https://doi.org/10.1159/000479984openalex-snapshot
Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function
inferredcites →https://doi.org/10.1186/2045-824x-6-18openalex-snapshot
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage
inferredcites →https://doi.org/10.1200/jco.2012.45.8372openalex-snapshot
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
inferredcites →https://doi.org/10.1200/jco.2012.48.4410openalex-snapshot
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
inferredcites →https://doi.org/10.1200/jco.2013.53.7746openalex-snapshot
SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
inferredcites →https://doi.org/10.1200/jco.2013.54.3298openalex-snapshot
Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
inferredcites →https://doi.org/10.1200/jco.2018.36.4_suppl.412openalex-snapshot
Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib.
inferredcites →https://doi.org/10.1200/jco.2019.37.4_suppl.317openalex-snapshot
Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT).
inferredcites →https://doi.org/10.3350/cmh.2017.0108openalex-snapshot
Treatment options after sorafenib failure in patients with hepatocellular carcinoma
inferredcites →https://doi.org/10.3350/cmh.2018.0090openalex-snapshot
Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update
inferredcites →https://doi.org/10.3350/cmh.2019.0021nopenalex-snapshot
Switching to systemic therapy after locoregional treatment failure: Definition and best timing
inferredcites →https://doi.org/10.3390/cancers11060841openalex-snapshot
Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life
inferredcites →https://doi.org/10.3390/cancers11111769openalex-snapshot
Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings
inferredcites →https://doi.org/10.3390/cancers12071867openalex-snapshot
Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study
inferredcites →https://doi.org/10.3748/wjg.v21.i25.7895openalex-snapshot
Thrombocytopenia for prediction of hepatocellular carcinoma recurrence: Systematic review and meta-analysis
inferredcites →https://doi.org/10.5009/gnl14460openalex-snapshot
2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4781315openalex-extracted
Deep Learning Radiopathomics Model for Predicting Vessels Encapsulating Tumor Clusters And Survival in Hepatocellular Carcinoma: A Multicenter Study
inferred← citeshttps://doi.org/10.1002/cam4.5123openalex-snapshot
Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation
inferred← citeshttps://doi.org/10.1002/cam4.5532openalex-snapshot
Phase 1 dose escalation study of FGFR4 inhibitor in combination with pembrolizumab in advanced solid tumors patients
inferred← citeshttps://doi.org/10.1002/cam4.5661openalex-snapshot
Effectiveness and safety of lenvatinib plus anti‐programmed death‐1 antibodies in patients with hepatocellular carcinoma: A real‐world cohort study
inferred← citeshttps://doi.org/10.1002/ygh2.477openalex-snapshot
Lenvatinib for unresectable hepatocellular carcinoma: the first Indian experience
inferred← citeshttps://doi.org/10.1007/s12072-022-10398-5openalex-snapshot
Lenvatinib for the treatment of hepatocellular carcinoma—a real-world multicenter Australian cohort study
inferred← citeshttps://doi.org/10.1007/s12672-024-01110-0openalex-snapshot
Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives
inferred← citeshttps://doi.org/10.1007/s40801-026-00554-wopenalex-snapshot
The Relevance of Lenvatinib in Advanced Hepatocellular Carcinoma: Insights from a Prospective Observational Cohort in South India
inferred← citeshttps://doi.org/10.1016/j.clinre.2022.102061openalex-snapshot
Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.jcis.2023.01.144openalex-snapshot
A multifunctional nanotheranostic agent based on Lenvatinib for multimodal synergistic hepatocellular carcinoma therapy with remarkably enhanced efficacy
inferred← citeshttps://doi.org/10.1016/j.jphs.2021.08.011openalex-snapshot
Impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of lenvatinib in patients with hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1038/s41598-022-11736-1openalex-snapshot
Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy
inferred← citeshttps://doi.org/10.1038/s41598-024-66766-8openalex-snapshot
The impact of lenvatinib on sarcopenia in patients with advanced unresectable hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1039/d1tb01808fopenalex-snapshot
Lenvatinib and Cu 2− x S nanocrystals co-encapsulated in poly( d , l -lactide- co -glycolide) for synergistic chemo-photothermal therapy against advanced hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1080/14796694.2024.2397328openalex-snapshot
Real-world safety and effectiveness of lenvatinib in unresectable hepatocellular carcinoma in Korea: post-marketing study
inferred← citeshttps://doi.org/10.1097/meg.0000000000002668openalex-snapshot
Efficacy and safety comparison between Lenvatinib and Sorafenib in hepatocellular carcinoma treatment: a systematic review and meta-analysis of real-world study
inferred← citeshttps://doi.org/10.1111/bph.70445openalex-snapshot
Hand–foot skin reaction as a positive prognostic factor in vascular endothelial growth factor receptor‐tyrosine kinase inhibitor treatment
inferred← citeshttps://doi.org/10.1111/hepr.13801openalex-snapshot
Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study
inferred← citeshttps://doi.org/10.1111/jgh.15727openalex-snapshot
Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1111/liv.15014openalex-snapshot
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib
inferred← citeshttps://doi.org/10.1111/liv.15953openalex-snapshot
Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy
inferred← citeshttps://doi.org/10.1148/rycan.240213openalex-snapshot
Deep Learning Radiopathomics Models Based on Contrast-enhanced MRI and Pathologic Imaging for Predicting Vessels Encapsulating Tumor Clusters and Prognosis in Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1159/000521746openalex-snapshot
Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study
inferred← citeshttps://doi.org/10.1159/000523849openalex-snapshot
Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study
inferred← citeshttps://doi.org/10.1159/000546185openalex-snapshot
Predicting Survival Outcomes in Patients with Hepatocellular Carcinoma Receiving Lenvatinib by Using the Up7-ALBI Score
inferred← citeshttps://doi.org/10.12669/pjms.39.6.7944openalex-snapshot
Impact of combining Lenvatinib with Transarterial chemoembolization for unresectable hepatocellular carcinoma
inferred← citeshttps://doi.org/10.17998/jlc.2022.11.07openalex-snapshot
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
inferred← citeshttps://doi.org/10.2147/jhc.s411748openalex-snapshot
Population Sensitive to Lenvatinib Plus Anti-PD-1 for Unresectable Hepatocellular Carcinoma Infected with Hepatitis B Virus
inferred← citeshttps://doi.org/10.2147/jhc.s548111openalex-snapshot
Real-World Comparison of Lenvatinib and Sorafenib as First-Line Treatments for Hepatocellular Carcinoma: A Multicenter Study
inferred← citeshttps://doi.org/10.2174/1568009623666230215142941openalex-snapshot
Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy Combined a Tyrosine Kinase Inhibitor for Treatment of Large Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.21873/anticanres.16112openalex-snapshot
Impact of Post-progression Survival on Outcomes of Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Retrospective Cohort Study
inferred← citeshttps://doi.org/10.2217/fon-2021-0242openalex-snapshot
Real-World Effectiveness of Lenvatinib Monotherapy Among Unresectable Hepatocellular Carcinoma Patients in the USA
inferred← citeshttps://doi.org/10.3348/kjr.2022.0822openalex-snapshot
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.3350/cmh.2022.0294openalex-snapshot
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
inferred← citeshttps://doi.org/10.3389/fonc.2021.788635openalex-snapshot
A Retrospective Study of Lenvatinib Monotherapy or Combined With Programmed Cell Death Protein 1 Antibody in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma in China
inferred← citeshttps://doi.org/10.3389/fonc.2022.888755openalex-snapshot
Safety and Efficacy of Liver-Directed Radiotherapy in Combination With Lenvatinib for Hepatocelluar Carcinoma With Macroscopic Tumor Thrombosis
inferred← citeshttps://doi.org/10.3389/fonc.2025.1627281openalex-snapshot
Case Report: Efficacy of preoperative conversion therapy with lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy in an advanced hepatocellular carcinoma
inferred← citeshttps://doi.org/10.3390/cancers14225525openalex-snapshot
Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.3390/cancers17030479openalex-snapshot
Long-Term Survival of Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in Real-World Clinical Practice
inferred← citeshttps://doi.org/10.3390/jcm10184045openalex-snapshot
Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study
inferred← citeshttps://doi.org/10.4251/wjgo.v17.i6.105887openalex-snapshot
Transarterial chemoembolization combined with lenvatinib vs transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.61186/ijrr.22.4.947openalex-snapshot
The efficacy and safety of transcatheter arterial chemoembolization combined with lenvatinib plus radiotherapy in the treatment of hepatocellular carcinoma: a meta-analysis
inferred← citeshttps://doi.org/10.7150/ijbs.96031openalex-snapshot
Deubiquitination of CIB1 by USP14 promotes lenvatinib resistance via the PAK1-ERK1/2 axis in hepatocellular carcinoma
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.